Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 11/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31196228 | 0.91 | LPAR1 (0.67) | LPAR1HRH1LPAR3CYP1A2CYP2C19 | |
| SCHEMBL14710295 | 0.85 | LPAR1 (0.61) | LPAR1HRH1LPAR3 | |
| SCHEMBL14710286 | 0.83 | LPAR1 (0.70) | LPAR1HRH1LPAR3 | |
| SCHEMBL31196388 | 0.82 | LPAR1 (0.46) | LPAR1HRH1LPAR3CYP1A2CYP2C19 | |
| SCHEMBL31196308 | 0.82 | LPAR1 (0.63) | LPAR1HRH1LPAR3 | |
| SCHEMBL31196247 | 0.79 | LPAR1 (0.65) | LPAR1HRH1LPAR3 | |
| SCHEMBL14790511 | 0.79 | LPAR1 (0.56) | LPAR1HRH1LPAR3 | |
| SCHEMBL31196134 | 0.78 | LPAR1 (0.70) | LPAR1HRH1LPAR3 | |
| SCHEMBL31196290 | 0.77 | LPAR1 (0.61) | LPAR1HRH1LPAR3ENPP2 | |
| SCHEMBL16697495 | 0.76 | LPAR1 (0.77) | LPAR1HRH1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | UNIV LAKEHEAD (CA) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | LPAR3, LPAR1, LPAR4 | LPAR1 2/4885HRH1 1387/4885LPAR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.